KASID
Search
- Page Path
- HOME > Search
Original Articles
- Evolution of surgical trends in Crohn’s disease during the biologic era: population-based cohort insights from Taiwan, a low-endemicity region
- Er-Hsiang Yang, Nai-Yu Chen, Ching-Lan Cheng, Yu-Ching Chang, Po-Chuan Chen, Lu-Hsuan Wu, Jui-Wen Kang, Hsueh-Chien Chiang, Po-Jun Chen, Bo-Wen Lin, Hsin-Yu Kuo, Chiao-Hsiung Chuang
- Received January 10, 2025 Accepted August 21, 2025 Published online November 25, 2025
- DOI: https://doi.org/10.5217/ir.2025.00003 [Epub ahead of print]
-
Abstract
PDF
Supplementary Material
PubReader
ePub - Background/Aims
Surgery remains a crucial treatment option for Crohn’s disease (CD), even with the introduction of biological agents. This nationwide cohort study in Taiwan investigates surgery trends and the impacts of biologics in a region with a low prevalence of CD.
Methods
This retrospective population-based cohort study used Taiwan’s National Health Insurance Database from 2003 to 2018. The cohort included 725 CD patients. Patient characteristics, surgery outcomes, and impact of the biologic era on surgical risk were analyzed.
Results
During the study period, 292 CD patients (40.3%) underwent surgery, with 125 in the pre-biologic era and 167 in the post-biologic era. The incidences of intestinal surgery (IS) and perianal surgery (PS) have significantly decreased. The cumulative probabilities of IS were 20%, 35%, and 44% after 1, 5, and 10 years, respectively; the PS incidences were 3%, 5%, and 7%, respectively. The cumulative incidence of IS was significantly lower in the post-biologic era compared to the pre-biologic era (P= 0.049). CD patients had high second IS incidences of 31% at 5 years after the first IS.
Conclusions
Our study demonstrates the surgical incidences have decreased in the biologic era but remained relatively high in a region with low disease prevalence. This suggests the need for further improvements in CD management.
- 1,002 View
- 128 Download
- IBD
- Incidence comparison of adverse events in patients with inflammatory bowel disease receiving different biologic agents: retrospective long-term evaluation
- Brigida Barberio, Edoardo Vincenzo Savarino, Timothy Card, Cristina Canova, Francesco Baldisser, Alessandro Gubbiotti, Davide Massimi, Matteo Ghisa, Fabiana Zingone
- Intest Res 2022;20(1):114-123. Published online August 4, 2021
- DOI: https://doi.org/10.5217/ir.2021.00037
-
Abstract
PDFSupplementary MaterialPubReaderePub
- Background/Aims
Current literature is lacking in studies comparing the incidence of adverse events (AEs) in patients with inflammatory bowel diseases (IBD) treated with adalimumab (ADA) or vedolizumab (VDZ) in a real-life scenario. Therefore, our primary aim was to compare the AEs occurring in patients taking ADA to those of patients taking VDZ.
Methods
In this single center study, data on AEs from IBD patients who underwent treatment with ADA and VDZ were retrospectively collected. AE rates per 100 person-years were calculated. A Cox regression model was used to estimate the hazard ratios of the AEs between the 2 drugs.
Results
A total of 16 ADA patients (17.2%) and 11 VDZ patients (7.6%) had AEs causing drug interruption during the study period (P=0.02). Most of the AEs were noninfectious extraintestinal events (50% in ADA and 54.5% in VDZ) while infections accounted for 31.2% of the AEs in patients treated with ADA and 27.3% in those treated with VDZ. The incidence rate of AEs causing withdrawal of therapy was 13.2 per 100 person-years for ADA and 5.3 per 100 person-years for VDZ, corresponding to a 76% lower risk in patients in VDZ. Considering the first year of treatment, we observed 34 subjects treated with ADA (36.5%) having at least 1 AEs and 57 (39.3%) among those taking VDZ (P=0.67).
Conclusions
VDZ has a lower incidence rate of AEs causing withdrawal of treatment compared to ADA but a similar risk of AEs not causing drug interruption. Real-life head-to-head studies are still necessary to further explore the safety profile of these drugs. -
Citations
Citations to this article as recorded by
- Risk of Spondyloarthritis in Patients With Inflammatory Bowel Disease Receiving Treatment With Biologics or Janus Kinase Inhibitors
Young-Eun Kim, Soo Min Ahn, Ji Seon Oh, Yong-Gil Kim, Chang-Keun Lee, Bin Yoo, Sung Wook Hwang, Byong Duk Ye, Suk-Kyun Yang, Sang Hyoung Park, Seokchan Hong
The Journal of Rheumatology.2026; 53(3): 260. CrossRef - Real‑world safety and efficacy of biological agents in inflammatory bowel disease: a one-year post-marketing pharmacovigilance observational study in the Calabria region
Antonio Fabiano, Caterina De Sarro, Domenico Frajia, Francesca Bosco, Lorenza Guarnieri, Stefano Ruga, Stefano Rodinò, Ladislava Sebkova, Enrico Ciliberto, Isidoro Buoncompagni, Laura Costantino, Antonio Leo, Gianmarco Marcianò, Vincenzo Rania, Rita Citra
Pharmacological Reports.2025; 77(5): 1415. CrossRef - CU06-1004 inhibits the progression of chronic colitis and colitis-associated colorectal cancer by suppressing inflammation
Dongyeop Kim, Yeomyeong Kim, Haiying Zhang, Ye-Seul Kim, Minyoung Noh, Cho-Rong Bae, Young-Guen Kwon, Sang-Jun Ha
Frontiers in Pharmacology.2025;[Epub] CrossRef - Impact of age at diagnosis on long‐term prognosis in patients with intestinal Behçet's disease
Ji Young Chang, Soo Jung Park, Jae Jun Park, Tae Il Kim, Jae Hee Cheon, Jihye Park
Journal of Gastroenterology and Hepatology.2024; 39(3): 519. CrossRef - Comparative Risk of Serious Infection With Vedolizumab vs Anti-Tumor Necrosis Factor in Inflammatory Bowel Disease: Results From Nationwide Swedish Registers
Sara Karlqvist, Michael C. Sachs, Carl Eriksson, Yang Cao, Scott Montgomery, Jonas F. Ludvigsson, Ola Olén, Jonas Halfvarson
American Journal of Gastroenterology.2024; 119(12): 2480. CrossRef - The effect of medical cannabis in inflammatory bowel disease: analysis from the UK Medical Cannabis Registry
Nishaanth Dalavaye, Simon Erridge, Martha Nicholas, Manaswini Pillai, Lara Bapir, Carl Holvey, Ross Coomber, James J Rucker, Jonathan Hoare, Mikael H Sodergren
Expert Review of Gastroenterology & Hepatology.2023; 17(1): 85. CrossRef - Infectious complications in patients with inflammatory bowel disease in Asia: the results of a multinational web-based survey in the 8th Asian Organization for Crohn’s and Colitis meeting
Yu Kyung Jun, Seong-Joon Koh, Dae Seong Myung, Sang Hyoung Park, Choon Jin Ooi, Ajit Sood, Jong Pil Im
Intestinal Research.2023; 21(3): 353. CrossRef - Beyond the survey, to the ideal therapy for Asian
Ki Jae Jo, Jong Pil Im
Intestinal Research.2023; 21(3): 280. CrossRef - Which biologic agents increase perioperative complications in patients with inflammatory bowel disease?
Jihye Park
Intestinal Research.2022; 20(1): 1. CrossRef - Feasibility of a Clinical Decision Support Tool for Ustekinumab to Predict Clinical Remission and Relapse in Patients With Crohn’s Disease: A Multicenter Observational Study
Jihye Park, Jaeyoung Chun, Hyuk Yoon, Jae Hee Cheon
Inflammatory Bowel Diseases.2022;[Epub] CrossRef - Personalized medicine in inflammatory bowel disease: Perspectives on Asia
Su Hyun Park, Sang Hyoung Park
Journal of Gastroenterology and Hepatology.2022; 37(8): 1434. CrossRef - Real-World Evidence of the Effectiveness and Safety of Ustekinumab for the Treatment of Crohn’s Disease: Systematic Review and Meta-Analysis of Observational Studies
Cristina Rubín de Célix, María Chaparro, Javier P. Gisbert
Journal of Clinical Medicine.2022; 11(14): 4202. CrossRef - Effectiveness and Safety of Golimumab in Patients with Ulcerative Colitis: A Multicenter, Prospective, Postmarketing Surveillance Study
Jongwook Yu, Soo Jung Park, Hyung Wook Kim, Yun Jeong Lim, Jihye Park, Jae Myung Cha, Byong Duk Ye, Tae Oh Kim, Hyun-Soo Kim, Hyun Seok Lee, Su Young Jung, Youngdoe Kim, Chang Hwan Choi
Gut and Liver.2022; 16(5): 764. CrossRef - Vedolizumab Is Safe and Efficacious for the Treatment of Pediatric-Onset Inflammatory Bowel Disease Patients Who Fail a Primary Biologic Agent
Sujin Choi, Eun Sil Kim, Yiyoung Kwon, Mi Jin Kim, Yon Ho Choe, Byung-Ho Choe, Ben Kang
Journal of Korean Medical Science.2022;[Epub] CrossRef
- Risk of Spondyloarthritis in Patients With Inflammatory Bowel Disease Receiving Treatment With Biologics or Janus Kinase Inhibitors
- 8,562 View
- 370 Download
- 14 Web of Science
- 14 Crossref
- Inflammatory bowel diseases
- Ustekinumab is effective in biological refractory Crohn’s disease patients–regardless of approval study selection criteria
- Sadik Saman, Martin Goetz, Judith Wendler, Nisar P. Malek, Jan Wehkamp, Thomas Klag
- Intest Res 2019;17(3):340-348. Published online May 31, 2019
- DOI: https://doi.org/10.5217/ir.2019.00012
-
Abstract
PDFPubReaderePub
- Background/Aims
Ustekinumab is effective in active Crohn’s disease. In a retrospective study we assessed the clinical outcome in nonresponders to anti-tumor necrosis factor therapy, and/or conventional therapy and/or the α4β7-integrin inhibitor vedolizumab. As approval study populations do not always reflect the average “real world” patient cohort, we assessed weather patients who would not have qualified for approval studies show similar outcomes.
Methods
Forty-one patients with mild to severe active Crohn’s disease were treated with ustekinumab (intravenous 6 mg per kg/body weight) followed by subcutaneous ustekinumab (90 mg) at week 8. Depending on the clinical response maintenance therapy was chosen every 8 or 12 weeks. Clinical response was defined by Crohn’s Disease Activity Index (CDAI) decline, decline of stool frequency or clinical improvement. Inclusion criteria for approval studies were assessed.
Results
The 58.5% (24/41) showed clinical response to ustekinumab. The 58.3% of this group (14/24) achieved clinical remission. Clinical response correlated significantly with drop of stool frequency and improvement of CDAI score. The 39 out of 41 patients had no side effects and we observed no serious infections. About a third of our patients would not have met ustekinumab approval study criteria. However, patients who did not meet study criteria showed clinical improvement numerically in the same range compared to patients who would have qualified for approval studies.
Conclusions
Ustekinumab is effective, safe and well tolerated in a highly therapy refractory patient cohort. Even though a reasonable number of patients did not meet ustekinumab approval study criteria, approval study results seem to be representative to the overall patient cohort. -
Citations
Citations to this article as recorded by- Comparative effectiveness and safety of ustekinumab at different intervals of maintenance phase in inflammatory bowel disease: a systematic review and meta-analysis
Yaqing Bai, Yinghao Sun, Qi He, Xiaoyin Bai, Hong Yang
European Journal of Gastroenterology & Hepatology.2024; 36(4): 359. CrossRef - Long-term real-world data of ustekinumab in Crohn’s disease: the Stockholm ustekinumab study
Francesca Bello, Samer Muhsen, Haider Sabhan, Alexandra Borin, Fredrik Johansson, Charlotte Höög, Ole Forsberg, Christina Wennerström, Charlotte Söderman, Mikael Lördal, Sven Almer
Therapeutic Advances in Gastroenterology.2024;[Epub] CrossRef - Effectiveness and Safety of Ustekinumab in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis
Sailish Honap, Susanna Meade, Hajir Ibraheim, Peter M. Irving, Michael P. Jones, Mark A. Samaan
Digestive Diseases and Sciences.2022; 67(3): 1018. CrossRef - Systematic review with meta‐analysis: loss of response and requirement of ustekinumab dose escalation in inflammatory bowel diseases
Hongsheng Yang, Bingyang Li, Qin Guo, Jian Tang, Bo Peng, Ni Ding, Miao Li, Qingfang Yang, Zicheng Huang, Na Diao, Xia Zhu, Jun Deng, Huili Guo, Pinjin Hu, Kang Chao, Xiang Gao
Alimentary Pharmacology & Therapeutics.2022; 55(7): 764. CrossRef - Clinically reversible ustekinumab-induced encephalopathy: case report and review of the literature
Jordi Sarto, Berta Caballol, Joan Berenguer, Iban Aldecoa, Álvaro Carbayo, Daniel Santana, Ivan Archilla, Carles Gaig, Francesc Graus, Julián Panés, Albert Saiz
Therapeutic Advances in Neurological Disorders.2022;[Epub] CrossRef - Safety and Efficacy of Ustekinumab in the Treatment of Crohn Disease: A Systematic Review and Meta-analysis
Mohammed Assem Khorshid, Ahmed Cordie, Sherief Abd-Elsalam
Journal of Coloproctology.2022; 42(02): 178. CrossRef - Real-World Evidence of the Effectiveness and Safety of Ustekinumab for the Treatment of Crohn’s Disease: Systematic Review and Meta-Analysis of Observational Studies
Cristina Rubín de Célix, María Chaparro, Javier P. Gisbert
Journal of Clinical Medicine.2022; 11(14): 4202. CrossRef - Management of inflammatory bowel disease beyond tumor necrosis factor inhibitors: novel biologics and small-molecule drugs
Soo-Young Na, You Sun Kim
The Korean Journal of Internal Medicine.2022; 37(5): 906. CrossRef - Prospective observational study on Stelara (ustekinumab) assessing effectiveness in Crohn’s disease (PROSE): a 16-week follow-up
Anders Forss, Mark Clements, Pär Myrelid, Hans Strid, Charlotte Söderman, Agnieszka Wagner, David Andersson, Fredrik Hjelm, Ola Olén, Jonas F. Ludvigsson, Jonas Halfvarson
Scandinavian Journal of Gastroenterology.2021; 56(6): 680. CrossRef - Efficacy and tolerability of infliximab retreatment in patients with inflammatory bowel disease: a systematic review and meta-analysis
Seungwon Yang, Siyoung Yang, Young Kwon Jo, Seungyeon Kim, Min Jung Chang, Junjeong Choi, Jae Hee Cheon, Yun Mi Yu
Therapeutic Advances in Chronic Disease.2021;[Epub] CrossRef - Treatment of inflammatory bowel diseases: focusing on biologic agents and new therapies
Hyo Yeop Song, Geom Seog Seo
Journal of the Korean Medical Association.2021; 64(9): 605. CrossRef - Eficacia y seguridad de ustekinumab en la práctica clínica real. Estudio multicéntrico retrospectivo. Cohorte ARAINF
Diego Casas Deza, Santiago García López, Miguel Lafuente Blasco, Raquel Vicente Lidón, Juan Nerín de la Puerta, Elena Peña Gonzalez, Yolanda Ber Nieto, Mara Charro Calvillo, María José Alcalá Escriche, Fernando Gomollón García, Maite Arroyo Villarino
Gastroenterología y Hepatología.2020; 43(3): 126. CrossRef - Effectiveness and safety of Ustekinumab for the treatment of Crohn’s disease in real-life experiences: a meta-analysis of observational studies
Fabio Salvatore Macaluso, Marcello Maida, Marco Ventimiglia, Mario Cottone, Ambrogio Orlando
Expert Opinion on Biological Therapy.2020; 20(2): 193. CrossRef - Efficacy and safety of ustekinumab in real clinical practice. Retrospective multicentre study. ARAINF cohort
Diego Casas Deza, Santiago García López, Miguel Lafuente Blasco, Raquel Vicente Lidón, Juan Nerín de la Puerta, Elena Peña Gonzalez, Yolanda Ber Nieto, Mara Charro Calvillo, María José Alcalá Escriche, Fernando Gomollón García, Maite Arroyo Villarino
Gastroenterología y Hepatología (English Edition).2020; 43(3): 126. CrossRef - Ustekinumab en enfermedad de Crohn: efectividad y seguridad en práctica clínica
Cristina Saldaña Dueñas, María Rullán Iriarte, Alfonso Elosua González, Cristina Rodríguez Gutiérrez, Saioa Rubio Iturria, Óscar Nantes Castillejo
Gastroenterología y Hepatología.2020; 43(9): 497. CrossRef - Real‐world long‐term effectiveness of ustekinumab in Crohn's disease: results from the ENEIDA registry
Marisa Iborra, Belén Beltrán, Agnes Fernández‐Clotet, Eva Iglesias‐Flores, Pablo Navarro, Montserrat Rivero, Ana Gutiérrez, Mónica Sierra‐Ausin, Francisco Mesonero, Rocío Ferreiro‐Iglesias, Joaquín Hinojosa, Xavier Calvet, Beatriz Sicilia, Carlos González
Alimentary Pharmacology & Therapeutics.2020; 52(6): 1017. CrossRef - Objectively assessed disease activity and drug persistence during ustekinumab treatment in a nationwide real-world Crohn’s disease cohort
Clas-Göran af Björkesten, Tuire Ilus, Taru Hallinen, Erkki Soini, Anja Eberl, Kalle Hakala, Mikko Heikura, Airi Jussila, Ritva Koskela, Inka Koskinen, Veikko Moilanen, Christian Nielsen, Urpo Nieminen, Heikki Nuutinen, Markku Heikkinen, Ulla-Maija Suhonen
European Journal of Gastroenterology & Hepatology.2020; 32(12): 1507. CrossRef - Ustekinumab in Crohn's disease: Effectiveness and safety in clinical practice
Cristina Saldaña Dueñas, María Rullán Iriarte, Alfonso Elosua González, Cristina Rodríguez Gutiérrez, Saioa Rubio Iturria, Óscar Nantes Castillejo
Gastroenterología y Hepatología (English Edition).2020; 43(9): 497. CrossRef - Editorial: real‐world short‐term effectiveness of ustekinumab in 305 patients with Crohn’s disease—results from the ENEIDA registry. Authors' reply
Marisa Iborra, Belén Beltrán, Pilar Nos
Alimentary Pharmacology & Therapeutics.2019; 50(5): 600. CrossRef
- Comparative effectiveness and safety of ustekinumab at different intervals of maintenance phase in inflammatory bowel disease: a systematic review and meta-analysis
- 10,938 View
- 279 Download
- 16 Web of Science
- 19 Crossref
- Inflammatory bowel diseases
- Risk of surgery in patients with stricturing type of Crohn’s disease at the initial diagnosis: a single center experience
- Yuji Maehata, Yutaka Nagata, Tomohiko Moriyama, Yuichi Matsuno, Atsushi Hirano, Junji Umeno, Takehiro Torisu, Tatsuya Manabe, Takanari Kitazono, Motohiro Esaki
- Intest Res 2019;17(3):357-364. Published online February 21, 2019
- DOI: https://doi.org/10.5217/ir.2018.00107
-
Abstract
PDFPubReaderePub
- Background/Aims
It remains uncertain which patients with stricturing-type Crohn’s disease (CD) require early small bowel surgery after the initial diagnosis. We aimed to clarify clinical characteristics associated with the intervention in such condition of CD.
Methods
We retrospectively evaluated the clinical course of 53 patients with CD and small bowel strictures who were initially treated with medications after the initial diagnosis. We investigated possible associations between small bowel surgery and the following: clinical factors and radiologic findings at initial diagnosis and the types of medications administered during follow-up.
Results
Twenty-eight patients (53%) required small bowel resection during a median follow-up period of 5.0 years (range, 0.5–14.3 years). The cumulative incidence rates of small bowel surgery at 2, 5, and 10 years were 26.4%, 41.0%, and 63.2%, respectively. Univariate analysis indicated that obstructive symptoms (P=0.036), long-segment stricture (P<0.0001), and prestenotic dilation (P<0.0001) on radiography were associated with small bowel surgery, and immunomodulatory (P=0.037) and biological therapy (P=0.008) were significant factors during follow-up. Multivariate analysis revealed that long-segment stricture (hazard ratio [HR], 4.25; 95% confidence interval [CI], 1.78–10.53; P=0.001) and prestenotic dilation (HR, 3.41; 95% CI, 1.24–9.62; P=0.018) on radiography showed a positive correlation with small bowel surgery, and biological therapy (HR, 0.40; 95% CI, 0.15–0.99; P=0.048) showed a negative correlation.
Conclusions
CD patients with long-segment stricture and prestenotic dilation on radiography seem to be at a higher risk of needing small bowel surgery. For such patients, early surgical intervention might be appropriate, even at initial diagnosis. -
Citations
Citations to this article as recorded by- Risk factors for stricture-related surgery in stricturing Crohn’s disease
Emil Yunusov, Betul Piyade, Ilkay Ergenc, Muhammed Enes Tasci, Nisanur Sariyar, Yesim Ozen Alahdab, Ozlen Atug, Haluk Tarik Kani
BMC Gastroenterology.2026;[Epub] CrossRef - Colonic strictures in Crohn’s disease: a non-surgical survival
Sarra Laabidi, Hamed Aboubecrine, Salma Souissi, Donia Gouiaa, Asma Labidi, Nadia Ben Mustapha, Anis Haddad, Amine Sebai, Meriem Serghini, Monia Fekih, Hanene Jaziri, Jalel Boubaker
Future Science OA.2025;[Epub] CrossRef - Crohn Disease Strictures: Multimodality Imaging to Identify Imaging Biomarkers
Safa Hoodeshenas, Jonathan R. Dillman, Stuart A. Taylor, Jordi Rimola, Bachir Taouli, Kathryn A. Robinson, Aiming Lu, David J. Bartlett, David H. Bruining, Catherine E. Hagen, Ajit H. Goenka, Shigao Chen, Florian Rieder, Brian Feagan, Mark E. Baker, Joel
RadioGraphics.2025;[Epub] CrossRef - Comprehensive review and update of stricturing Crohn’s disease
Alexander T. Elford, Zaid Ardalan, Paul Simkin, Britt Christensen
Indian Journal of Gastroenterology.2024; 43(1): 64. CrossRef - A global consensus on the definitions, diagnosis and management of fibrostenosing small bowel Crohn’s disease in clinical practice
Dominik Bettenworth, Mark E. Baker, Joel G. Fletcher, Vipul Jairath, Cathy Lu, Willem Bemelman, Geert d’Haens, Andre d’Hoore, Axel Dignass, Iris Dotan, Roger Feakins, Phillip Fleshner, Christina Ha, Gaylyn Henderson, Ruishen Lyu, Julian Panes, Gerhard Rog
Nature Reviews Gastroenterology & Hepatology.2024; 21(8): 572. CrossRef - Reliability of MR Enterography Features for Describing Fibrostenosing Crohn Disease
Florian Rieder, Mark E. Baker, David H. Bruining, Jeff L. Fidler, Eric C. Ehman, Shannon P. Sheedy, Jay P. Heiken, Justin M. Ream, David R. Holmes, Akitoshi Inoue, Payam Mohammadinejad, Yong S. Lee, Stuart A. Taylor, Jaap Stoker, Guangyong Zou, Zhongya Wa
Radiology.2024;[Epub] CrossRef - Reliability of CT Enterography for Describing Fibrostenosing Crohn Disease
Florian Rieder, Christopher Ma, Jurij Hanzel, Joel G. Fletcher, Mark E. Baker, Zhongya Wang, Leonardo Guizzetti, Lisa M. Shackelton, Julie Rémillard, Mihir Patel, Jiafei Niu, Ronald Ottichilo, Cynthia S. Santillan, Nunzia Capozzi, Stuart A. Taylor, David
Radiology.2024;[Epub] CrossRef - Use of oral diet and nutrition support in management of stricturing and fistulizing Crohn's disease
Kush Fansiwala, Neha D. Shah, Kelly A. McNulty, Mary R. Kwaan, Berkeley N. Limketkai
Nutrition in Clinical Practice.2023; 38(6): 1282. CrossRef - Sarcopenia hinders the decline in disease activity after surgery for people with Crohn's disease: Preliminary results
Asuka Yasueda, Yuki Sekido, Takashi Takeda, Takayuki Ogino, Norikatsu Miyoshi, Hidekazu Takahashi, Mamoru Uemura, Yuichiro Doki, Hidetoshi Eguchi, Tsunekazu Mizushima
Nutrition.2022; 94: 111526. CrossRef - Efficacy of drug and endoscopic treatment of Crohn's disease strictures: A systematic review
Julien D Schulberg, Emily K Wright, Bronte A Holt, Helen E Wilding, Amy L Hamilton, Alyson L Ross, Michael A Kamm
Journal of Gastroenterology and Hepatology.2021; 36(2): 344. CrossRef - Comparison of Long-term Outcomes of Infliximab versus Adalimumab in 1,488 Biologic-Naive Korean Patients with Crohn’s Disease
Yoon Suk Jung, Minkyung Han, Sohee Park, Jae Hee Cheon
Gut and Liver.2021; 15(1): 92. CrossRef - Molecular targets and the use of biologics in the management of small bowel fibrosis in inflammatory bowel disease
Muaad Abdulla, Thean Soon Chew
Current Opinion in Gastroenterology.2021; 37(3): 275. CrossRef - Real world analysis on the efficacy and safety of anti-tumor necrosis factor therapy in patients with stricturing Crohn’s disease
Sudheer K. Vuyyuru, Bhaskar Kante, Peeyush Kumar, Pabitra Sahu, Saurabh Kedia, Mukesh Kumar Ranjan, Raju Sharma, Rajesh Panwar, Govind Makharia, Vineet Ahuja
Scientific Reports.2021;[Epub] CrossRef - Inpatient Management of Inflammatory Bowel Disease-Related Complications
Manreet Kaur, Robin L. Dalal, Seth Shaffer, David A. Schwartz, David T. Rubin
Clinical Gastroenterology and Hepatology.2020; 18(6): 1346. CrossRef - Surgical treatment of intestinal stricture in inflammatory bowel disease
Helen M. Mohan, John C. Coffey
Journal of Digestive Diseases.2020; 21(6): 355. CrossRef
- Risk factors for stricture-related surgery in stricturing Crohn’s disease
- 10,310 View
- 192 Download
- 15 Web of Science
- 15 Crossref
First
Prev
